Literature DB >> 28424834

Effect of prior foot shock stress and Δ9-tetrahydrocannabinol, cannabidiolic acid, and cannabidiol on anxiety-like responding in the light-dark emergence test in rats.

Erin M Rock1, Cheryl L Limebeer1, Gavin N Petrie1, Lauren A Williams1, Raphael Mechoulam2, Linda A Parker3.   

Abstract

RATIONALE: Cannabis is commonly used by humans to relieve stress. OBJECTIVES AND METHODS: Here, we evaluate the potential of intraperitoneally (i.p.) administered Δ9-tetrahydrocannabiol (THC) and cannabidiolic acid (CBDA, the precursor of cannabidiol [CBD]) to produce dose-dependent effects on anxiety-like responding in the light-dark (LD) emergence test of anxiety-like responding in rats, when administered acutely or chronically (21 days). As well, we evaluate the potential of THC, CBDA, and CBD to reduce anxiogenic responding produced by foot shock (FS) stress 24 h prior to the LD test.
RESULTS: In the absence of the explicit FS stressor, THC (1 and 10 mg/kg) produced anxiogenic-like responding when administered acutely or chronically, but CBDA produced neither anxiogenic- nor anxiolytic-like responding. Administration of FS stress 24 h prior to the LD test enhanced anxiogenic-like responding (reduced time spent and increased latency to enter the light compartment) in rats pretreated with either vehicle (VEH) or THC (1 mg/kg); however, administration of CBDA (0.1-100 μg/kg) or CBD (5 mg/kg) prevented the FS-induced anxiogenic-like responding (an anxiolytic-like effect). The 5-hydroxytryptamine 1A (5-HT1A) receptor antagonist, WAY100635, reversed CBDA's anxiolytic effect (1 μg/kg). Combining an anxiolytic dose of CBDA (1 μg/kg) or CBD (5 mg/kg) with an anxiogenic dose of THC (1 mg/kg) did not modify THC's anxiogenic effect.
CONCLUSION: These results suggest the anxiolytic effects of CBDA and CBD may require the presence of a specific stressor.

Entities:  

Keywords:  Anxiety; Anxiolytic; Cannabidiol; Cannabidiolic acid; Foot shock; Light-dark emergence test; Rat; Stress; Δ9-tetrahydrocannabiol

Mesh:

Substances:

Year:  2017        PMID: 28424834     DOI: 10.1007/s00213-017-4626-5

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  46 in total

1.  Reasons for cannabis use in psychosis.

Authors:  David Schofield; Chris Tennant; Louise Nash; Louisa Degenhardt; Alison Cornish; Coletta Hobbs; Gail Brennan
Journal:  Aust N Z J Psychiatry       Date:  2006 Jun-Jul       Impact factor: 5.744

2.  Behavioural and biochemical evidence for interactions between Delta 9-tetrahydrocannabinol and nicotine.

Authors:  Emmanuel Valjent; Jennifer M Mitchell; Marie-Jo Besson; Jocelyne Caboche; Rafael Maldonado
Journal:  Br J Pharmacol       Date:  2002-01       Impact factor: 8.739

3.  Anxiolytic-like effect of cannabidiol in the rat Vogel conflict test.

Authors:  Fabrício A Moreira; Daniele C Aguiar; Francisco S Guimarães
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2006-07-31       Impact factor: 5.067

4.  Corticosterone response to the plus-maze: high correlation with risk assessment in rats and mice.

Authors:  R J Rodgers; J Haller; A Holmes; J Halasz; T J Walton; P F Brain
Journal:  Physiol Behav       Date:  1999 Dec 1-15

5.  Differential anxiogenic, aversive, and locomotor effects of THC in adolescent and adult rats.

Authors:  Nicole L Schramm-Sapyta; Young May Cha; Saba Chaudhry; Wilkie A Wilson; H Scott Swartzwelder; Cynthia M Kuhn
Journal:  Psychopharmacology (Berl)       Date:  2007-01-09       Impact factor: 4.530

6.  Effects of intra-prelimbic prefrontal cortex injection of cannabidiol on anxiety-like behavior: involvement of 5HT1A receptors and previous stressful experience.

Authors:  M V Fogaça; F M C V Reis; A C Campos; F S Guimarães
Journal:  Eur Neuropsychopharmacol       Date:  2013-10-31       Impact factor: 4.600

7.  Individual differences in the effects of cannabinoids on motor activity, dopaminergic activity and DARPP-32 phosphorylation in distinct regions of the brain.

Authors:  Alexia Polissidis; Olga Chouliara; Andreas Galanopoulos; Georgia Rentesi; Maria Dosi; Thomas Hyphantis; Marios Marselos; Zeta Papadopoulou-Daifoti; George G Nomikos; Christina Spyraki; Eleni T Tzavara; Katerina Antoniou
Journal:  Int J Neuropsychopharmacol       Date:  2009-11-27       Impact factor: 5.176

8.  Facilitation of contextual fear memory extinction and anti-anxiogenic effects of AM404 and cannabidiol in conditioned rats.

Authors:  Rafael M Bitencourt; Fabrício A Pamplona; Reinaldo N Takahashi
Journal:  Eur Neuropsychopharmacol       Date:  2008-08-15       Impact factor: 4.600

9.  Cannabinoid pharmacological properties common to other centrally acting drugs.

Authors:  Jenny L Wiley; Billy R Martin
Journal:  Eur J Pharmacol       Date:  2003-06-27       Impact factor: 4.432

10.  Acute effects of delta-9-tetrahydrocannabinol, cannabidiol and their combination on facial emotion recognition: a randomised, double-blind, placebo-controlled study in cannabis users.

Authors:  Chandni Hindocha; Tom P Freeman; Grainne Schafer; Chelsea Gardener; Ravi K Das; Celia J A Morgan; H Valerie Curran
Journal:  Eur Neuropsychopharmacol       Date:  2014-12-05       Impact factor: 4.600

View more
  22 in total

1.  Effect of footshock stress on place conditioning produced by Δ9-tetrahydrocannabinol and the fatty acid amide hydrolase (FAAH) inhibitor, URB597, in Sprague-Dawley rats.

Authors:  Marieka V DeVuono; Kiri L Wills; Danielle V MacPherson; Kelly M Hrelja; Linda A Parker
Journal:  Psychopharmacology (Berl)       Date:  2017-08-12       Impact factor: 4.530

2.  Constituents of Cannabis Sativa.

Authors:  Erin M Rock; Linda A Parker
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

3.  Single and combined effects of plant-derived and synthetic cannabinoids on cognition and cannabinoid-associated withdrawal signs in mice.

Authors:  Alyssa M Myers; Patrick B Siegele; Jeffrey D Foss; Ronald F Tuma; Sara Jane Ward
Journal:  Br J Pharmacol       Date:  2018-03-01       Impact factor: 8.739

4.  Conditioned aversive responses produced by delayed, but not immediate, exposure to cocaine and morphine in male Sprague-Dawley rats.

Authors:  Kelsey G Guenther; Cassidy E Wideman; Erin M Rock; Cheryl L Limebeer; Linda A Parker
Journal:  Psychopharmacology (Berl)       Date:  2018-09-24       Impact factor: 4.530

5.  Cannabidiolic acid methyl ester, a stable synthetic analogue of cannabidiolic acid, can produce 5-HT1A receptor-mediated suppression of nausea and anxiety in rats.

Authors:  Roger G Pertwee; Erin M Rock; Kelsey Guenther; Cheryl L Limebeer; Lesley A Stevenson; Christeene Haj; Reem Smoum; Linda A Parker; Raphael Mechoulam
Journal:  Br J Pharmacol       Date:  2017-12-05       Impact factor: 8.739

6.  Decreased sensitivity in adolescent versus adult rats to the antidepressant-like effects of cannabidiol.

Authors:  Cristian Bis-Humbert; Rubén García-Cabrerizo; M Julia García-Fuster
Journal:  Psychopharmacology (Berl)       Date:  2020-02-21       Impact factor: 4.530

7.  Cannabidiol Interferes with Establishment of Δ9-Tetrahydrocannabinol-Induced Nausea Through a 5-HT1A Mechanism.

Authors:  Marieka V DeVuono; Olivia La Caprara; Gavin N Petrie; Cheryl L Limebeer; Erin M Rock; Matthew N Hill; Linda A Parker
Journal:  Cannabis Cannabinoid Res       Date:  2020-12-21

8.  Adolescent exposure to delta-9-tetrahydrocannabinol and ethanol heightens sensitivity to fear stimuli.

Authors:  Cora E Smiley; Heyam K Saleh; Katherine E Nimchuk; Constanza Garcia-Keller; Justin T Gass
Journal:  Behav Brain Res       Date:  2021-08-10       Impact factor: 3.352

9.  Reducing Effect of Cannabidiol on Alcohol Self-Administration in Sardinian Alcohol-Preferring Rats.

Authors:  Paola Maccioni; Jessica Bratzu; Mauro A M Carai; Giancarlo Colombo; Gian Luigi Gessa
Journal:  Cannabis Cannabinoid Res       Date:  2021-03-11

10.  Cannabis constituents interact at the drug efflux pump BCRP to markedly increase plasma cannabidiolic acid concentrations.

Authors:  Lyndsey L Anderson; Maia G Etchart; Dilara Bahceci; Taliesin A Golembiewski; Jonathon C Arnold
Journal:  Sci Rep       Date:  2021-07-22       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.